Veracyte Announces Multiple Studies Reinforcing the Value of Decipher Prostate Testing Will Be Presented at ASTRO 2023

Veracyte, Inc. announced that six abstracts highlighting new data from studies evaluating the company’s Decipher Prostate Genomic Classifier and related capabilities will be presented, three as...

Related Keywords

United States ,New York ,San Diego ,California ,University Of California Los Angeles ,Massachusetts ,South San Francisco ,San Diego Convention Center ,Ryan Phillips ,John Nikitas ,Angela Jia ,Alexander Allen ,Marshall Diven ,Elai Davicioni ,Ariel Marciscano ,University Of Maryland Medical Center ,Nasdaq ,Case Western Reserve University ,American Society For Radiation Oncology ,Twitter ,Decipher Genomics Research For Intelligent Discovery ,Veracyte Inc ,Research Use ,Decipher Prostate Genomic Classifier ,American Society ,Radiation Oncology ,Annual Meeting ,Decipher Prostate ,Decipher Genomics Research ,Intelligent Discovery ,Genomic Classifier ,Androgen Suppression ,Localized High Risk Prostate Cancer ,Mayo Clinic ,Comparison Individual Patient Level Analysis ,Three Gene Expression Signatures ,Localized Prostate ,Genomic Tests ,Black Men ,Prostate Cancer ,Maryland Medical Center ,Neoadjuvant Stereotactic Body Radiation Therapy ,High Risk Prostate Cancer ,Massachusetts General Hospital ,Genomic Classifier Scores ,Transcriptomic Data ,Prostate Cancer Distant Metastasis Risk ,Multicenter Retrospective Study ,California Los Angeles ,Molecular Subtype Classification ,New York Presbyterian Brooklyn Methodist Hospital ,Annual Report ,Quarterly Report ,Markets ,